Literature DB >> 15755515

Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse.

Abdeslem El Idrissi1, Xiao-Hua Ding, Jason Scalia, Ekkhart Trenkner, W Ted Brown, Carl Dobkin.   

Abstract

The fragile X mental retardation syndrome is due to the transcriptional silence of the fragile X gene, FMR1, and to the resulting loss of the FMR1 product, FMRP. The pathogenesis of the syndrome, however, is not understood. Increased prevalence of childhood seizures is a feature of the fragile X syndrome and increased seizure susceptibility is seen in the fragile X knock out mouse model for this disorder. To investigate the increased seizure susceptibility, we examined GABA(A) receptor expression in the FVB/N fragile X mouse. Western blot analysis revealed that expression of the GABA(A) receptor beta subunit (GABA(A) beta), which is required for receptor function, was reduced in the cortex, hippocampus, diencephalon and brainstem in adult male fragile X mice. Immunohistochemical analysis of brain sections indicated a reduction in GABA(A) beta immunoreactivity. We also found increased expression of glutamic acid decarboxylase, the enzyme responsible for GABA synthesis, in the same regions that showed GABA(A) beta reduction. These results indicate that the absence of Fmrp leads to GABAergic system alterations that could account for the increased seizure susceptibility of the fragile X mouse. These alterations may also be relevant to the seizures and the abnormal behaviors in the human syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15755515     DOI: 10.1016/j.neulet.2004.11.087

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  90 in total

1.  Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Authors:  Laura K K Pacey; Sujeenthar Tharmalingam; David R Hampson
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

Review 2.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

Review 3.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

Review 4.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 5.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

6.  Translational regulation of NeuroD1 expression by FMRP: involvement in glutamatergic neuronal differentiation of cultured rat primary neural progenitor cells.

Authors:  Se Jin Jeon; Ji-Woon Kim; Ki Chan Kim; So Min Han; Hyo Sang Go; Jung Eun Seo; Chang Soon Choi; Jong Hoon Ryu; Chan Young Shin; Mi-Ryoung Song
Journal:  Cell Mol Neurobiol       Date:  2013-12-12       Impact factor: 5.046

7.  The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.

Authors:  Jose Luis Olmos-Serrano; Joshua G Corbin; Mark P Burns
Journal:  Dev Neurosci       Date:  2011-11-08       Impact factor: 2.984

8.  Fragile X mental retardation protein in the driver's seat.

Authors:  Jay E Brenman
Journal:  Cereb Cortex       Date:  2009-04-22       Impact factor: 5.357

9.  Regulation of GABAA receptors by fragile X mental retardation protein.

Authors:  Baosong Liu; Lijun Li; Juan Chen; Zefen Wang; Zhiqiang Li; Qi Wan
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-09-10

Review 10.  The translation of translational control by FMRP: therapeutic targets for FXS.

Authors:  Jennifer C Darnell; Eric Klann
Journal:  Nat Neurosci       Date:  2013-04-14       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.